Victoria Socha

DocwireNews

During a poster session at the NKF 2022 Spring Clinical Meetings, Amy Larkin and colleagues reported on an assessment of the effect of online education designed to initiate changes in clinical practice related to management of hyperkalemia in order to enable and/or optimize use of renin-angiotensin-aldosterone system (RAAS) inhibitors. The poster was titled Impact of Online CME on Planned and Actual Practice Changes Related to Hyperkalemia Management.The CME activity included a 30-minute online video roundtable panel discussion among three experts in the role of potassium binders in enabling use of RAAS inhibitors and mineralocorticoid receptor antagonist in patients with various comorbidities. A survey administered immediately following the education activity was used to assess the impact of the activity on performance outcomes. The survey also identified planned changes in clinician practice as a result of participation in the CME activityEight weeks after completion of the activity, participants were contacted to assess self-reported actual changes in practice. The activity launched October 6, 2020, and data were collected through April 30, 2021.The survey immediately following the online education activity was completed by a total of 275 clinicians (91 nephrologists, 75 cardiologists, and 109 nurse practitioners/physicians assistants [NPs/PAs]). Nineteen percent of the nephrologists, 8% of the cardiologists, and 4% of the NPs/PAs were treating more than 100 patients per month taking RAAS inhibitors.Of the overall responding cohort, 91% indicated an average of 3.2 planned practice changes each. When re-engaged with the follow-up survey, 28 participants responded (12 nephrologists, 6 cardiologists, and 10 NPs/PAs). Of those, 86% reported an average of 3.9 changes in practice as a result of the CME activity.The practice changes included: (1) consider a loop diuretic to increase potassium clearance and enhance volume management (67% nephrologists, 83% cardiologists, 50% NPs/PAs); (2) review medications, diet, and over-the-counter medications to identify factors contributing to hyperkalemia (58% nephrologists, 83% cardiologists, 70% NAs/PAs); (3) control hyperkalemia with a novel potassium binder to optimize dose of RAAS inhibitor (58% nephrologists, 33% cardiologists, 50% NPs/PAs); (4) use of patiromer in patients on spironolactone to maintain normokalaemia and allow for spironolactone continuation of dose uptitration per the PEARL-HF study (58% nephrologists, 33% cardiologists, 40% NPs/ PAs).In summary, the authors said, &ldquo;The outcomes gathered in this assessment provide compelling evidence that participation in a 30-minute online video discussion among three experts prompted both planned and actual changes in practice to provide belter hyperkalemia management to their patients.&rdquo;Source: Larkin A, Blatherwick D, Boutsalis G. Impact of online CME on planned and actual practice changes related to hyperkalemia management. Abstract of a poster presented at the National Kidney Foundation Spring Clinical Meetings 2022 (Abstract #294), Boston, Massachusetts, April 6-10, 2022.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Changes in Hyperkalemia Management After Online CME

Hyperkalemia

During a poster session at the NKF 2022 Spring Clinical Meetings, Amy Larkin and colleagues reported on an assessment of the effect of online education designed to initiate ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe